Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S)

<p><strong>Article full text</strong></p> <p><br> The full text of this article can be found <a href="https://link.springer.com/article/10.1007/s13300-017-0299-7"><b>here</b>.</a><br> <br> <strong>Provide enhanced content for this article</strong><br> If you are an author of this publication and would like to provide additional enhanced content for your article then please contact <u>[email protected]</u>.<br> <br> The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.<br> <br> Other enhanced features include, but are not limited to:<br> • Slide decks<br> • Videos and animations<br> • Audio abstracts<br> • Audio slides</p> <p> </p

Correction: A Genome-Wide Association Study for Diabetic Retinopathy in a Japanese Population: Potential Association with a Long Intergenic Non-Coding RNA

<p>Correction: A Genome-Wide Association Study for Diabetic Retinopathy in a Japanese Population: Potential Association with a Long Intergenic Non-Coding RNA</p

Regional association plot of the region around the SNP rs9362054.

<p>The -log₁₀P values of the Fisher's exact test under the allele model in the GWAS of diabetic retinopathy in stage 1 were plotted against relative chromosomal locations (UCSC human genome 19).</p

Summary of the study strategy.

<p>Summary of the study strategy.</p

Associations of rs9362054 in <i>RP1-90L14.1</i> with diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and diabetic nephropathy (DN) in each stage and combined stages 1, 2 and 3, using logistic regression under genotype, dominant and recessive models after adjusting for sex, duration of diabetes and HbA1c.

a<p>With additive genetic effect.</p><p>Associations of rs9362054 in <i>RP1-90L14.1</i> with diabetic retinopathy (DR), proliferative diabetic retinopathy (PDR) and diabetic nephropathy (DN) in each stage and combined stages 1, 2 and 3, using logistic regression under genotype, dominant and recessive models after adjusting for sex, duration of diabetes and HbA1c.</p

Clinical features of Japanese patients with type 2 diabetes.

<p>DR: diabetic retinopathy, PDR: proliferative diabetic retinopathy; DN: diabetic nephropathy, SMU: Saitama Medical University Hospital, SSI: Saitama Social Insurance Hospital, KU: Keio University Hospital, NCGM: National Center for Global Health and Medicine Center Hospital.</p><p>Data are % or mean +− SD.</p>a<p><i>P</i><0.05 vs patients without DR.</p><p>Clinical features of Japanese patients with type 2 diabetes.</p

SNPs showing associations with diabetic retinopathy (DR) in combined stages 1 and 2 samples with <i>P</i><10⁻³ using the allele model.

<p>SNPs showing associations with diabetic retinopathy (DR) in combined stages 1 and 2 samples with <i>P</i><10⁻³ using the allele model.</p

Manhattan plot for the GWAS of diabetic retinopathy in stage 1.

<p><i>P</i> values of the Fisher's exact test under the allele model for SNPs in 446 patients were shown.</p